Literature DB >> 23791390

Comparison of the effectiveness of Conners' CPT and the CPT-identical pairs at distinguishing between smokers and nonsmokers with schizophrenia.

Michelle Roth1, L Elliot Hong, Robert P McMahon, Rebecca L Fuller.   

Abstract

Sustained attention deficits and high rates of smoking are often observed in patients with schizophrenia. This has led to the hypothesis that patients may smoke as an attempt to ameliorate cognitive deficits related to abnormal nicotinic structure and function. Continuous performance tasks (CPT) are often used to index sustained attention deficits in patients with schizophrenia, however, there are important differences between tasks that may impact performance in smokers and nonsmokers with schizophrenia differently. The Conners' CPT (C-CPT) has a high signal-to-noise ratio and is commonly used to assess impulsivity. The CPT-Identical Pairs (CPT-IP) has a low signal-to-noise ratio and is commonly used to assess negative symptoms in patients with schizophrenia. We sought to determine whether there were differences of sustained attention between patient smokers vs. nonsmokers, and if one CPT would provide a better separation of sustained attention between groups. Results revealed that both instruments detect more impaired sustained attention deficits in patient smokers compared to nonsmokers. Patient smokers performed significantly worse on the majority of the CPT-IP composite scores compared to the C-CPT composite scores. These results do not support the self-medication theory, as patient smokers performed worse than patient nonsmokers. Researchers studying sustained attention in schizophrenia may wish to consider the CPT-IP over the C-CPT, as well as control for smoking status.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Continuous performance tasks; Nicotine; Schizophrenia; Sustained attention

Mesh:

Year:  2013        PMID: 23791390      PMCID: PMC3732498          DOI: 10.1016/j.schres.2013.06.012

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  15 in total

1.  Effects of smoking history on selective attention in schizophrenia.

Authors:  Constanze Hahn; Eric Hahn; Michael Dettling; Onur Güntürkün; Thi Minh Tam Ta; Andres H Neuhaus
Journal:  Neuropharmacology       Date:  2012-01-11       Impact factor: 5.250

Review 2.  Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

3.  The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance.

Authors:  J Endicott; R L Spitzer; J L Fleiss; J Cohen
Journal:  Arch Gen Psychiatry       Date:  1976-06

4.  The Continuous Performance Test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families.

Authors:  B A Cornblatt; N J Risch; G Faris; D Friedman; L Erlenmeyer-Kimling
Journal:  Psychiatry Res       Date:  1988-11       Impact factor: 3.222

5.  Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status.

Authors:  Victoria C Wing; Ingrid Bacher; Kristi A Sacco; Tony P George
Journal:  Psychiatry Res       Date:  2011-06-12       Impact factor: 3.222

6.  Cognitive performance and smoking in first-episode psychosis: the self-medication hypothesis.

Authors:  Rafael Segarra; Arantzazu Zabala; Jose Ignacio Eguíluz; Natalia Ojeda; Edorta Elizagarate; Pedro Sánchez; Javier Ballesteros; Miguel Gutiérrez
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2010-09-14       Impact factor: 5.270

7.  Effects of nicotine nasal spray on cognitive function in schizophrenia.

Authors:  Robert C Smith; Jessy Warner-Cohen; Melissa Matute; Erin Butler; Erin Kelly; Sumathi Vaidhyanathaswamy; Alea Khan
Journal:  Neuropsychopharmacology       Date:  2006-03       Impact factor: 7.853

8.  Nicotine-haloperidol interactions and cognitive performance in schizophrenics.

Authors:  E D Levin; W Wilson; J E Rose; J McEvoy
Journal:  Neuropsychopharmacology       Date:  1996-11       Impact factor: 7.853

9.  The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls.

Authors:  Ruth S Barr; Melissa A Culhane; Lindsay E Jubelt; Rana S Mufti; Michael A Dyer; Anthony P Weiss; Thilo Deckersbach; John F Kelly; Oliver Freudenreich; Donald C Goff; A Eden Evins
Journal:  Neuropsychopharmacology       Date:  2007-04-18       Impact factor: 7.853

10.  High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia.

Authors:  Michael A Dyer; Oliver Freudenreich; Melissa A Culhane; Gladys N Pachas; Thilo Deckersbach; Erin Murphy; Donald C Goff; A Eden Evins
Journal:  Schizophr Res       Date:  2008-03-05       Impact factor: 4.939

View more
  3 in total

1.  Smoking normalizes cerebral blood flow and oxygen consumption after 12-hour abstention.

Authors:  Manouchehr S Vafaee; Albert Gjedde; Nasrin Imamirad; Kim Vang; Mallar M Chakravarty; Jason P Lerch; Paul Cumming
Journal:  J Cereb Blood Flow Metab       Date:  2015-03-31       Impact factor: 6.200

Review 2.  Heritability of Neuropsychological Measures in Schizophrenia and Nonpsychiatric Populations: A Systematic Review and Meta-analysis.

Authors:  Gabriëlla A M Blokland; Raquelle I Mesholam-Gately; Timothea Toulopoulou; Elisabetta C Del Re; Max Lam; Lynn E DeLisi; Gary Donohoe; James T R Walters; Larry J Seidman; Tracey L Petryshen
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

Review 3.  Memory and cognition in schizophrenia.

Authors:  J Y Guo; J D Ragland; C S Carter
Journal:  Mol Psychiatry       Date:  2018-09-21       Impact factor: 15.992

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.